Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension
Ophthalmology Retina · 2026-11 · 10 (11) · 1100-1110
DOI: 10.1016/j.oret.2026.06.032 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2026-11. Verfasst von Justus G Garweg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland; Department of Ophthalmology, Inselspital (Bern Univ…. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Visual Acuity, Wet Macular Degeneration. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG, Regeneron Pharmaceuticals Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland; Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, Bern, Switzerland. Electronic ad…
- Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
- Bayer Consumer Care AG, Basel, Switzerland.
- Bayer AG, Berlin, Germany.
- Augenarzt-Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, Bern, Switzerland; Department of Ophthalmology, Feinberg School…
- Hospital Clínic de Barcelona, Barcelona, Spain; Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.
Förderung
- Bayer AG
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Garweg, J. G., Chaudhary, V., Zhang, X., Leal, S., Machewitz, T., Munk, M. R., Zarranz-Ventura, J., Stahl, A., Lanzetta, P., & PULSAR Study Investigators (2026). Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension. Ophthalmology Retina, 10(11), 1100-1110. https://doi.org/10.1016/j.oret.2026.06.032
Vancouver
Garweg JG, Chaudhary V, Zhang X, Leal S, Machewitz T, Munk MR, et al. Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension. Ophthalmology Retina. 2026;10(11):1100-1110. doi:10.1016/j.oret.2026.06.032
BibTeX
@article{Garweg2026,
author = {Garweg, Justus G and Chaudhary, Varun and Zhang, Xin and Leal, Sergio and Machewitz, Tobias and Munk, Marion R and Zarranz-Ventura, Javier and Stahl, Andreas and Lanzetta, Paolo and PULSAR Study Investigators, PULSAR Study Investigators},
title = {Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension},
journal = {Ophthalmology Retina},
year = {2026},
volume = {10},
number = {11},
pages = {1100--1110},
doi = {10.1016/j.oret.2026.06.032}
}
EUVIMED